New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 12

Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

, , ,

Video content above is prompted by the following:

  • How would you sequence epcoritamab, a CD20xCD3 bispecific antibody for patients with R/R DLBCL who have progressed beyond CAR T-cell therapy?
  • How would you sequence glofitamab-gxbm, a CD20xCD3 bispecific antibody for patients with R/R DLBCL who have progressed beyond CAR T-cell therapy?